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ABSTRACT: The Institute for Quality and Efficiency in Health Care (IQWiG) was estab-
lished in 2004 to provide Germany’s Federal Joint Committee with evidence-based evalu-
ations of the benefits and cost benefits of health services, and functions in an advisory role. 
IQWiG reviews available evidence and produces recommendations after an extensive pro-
cess of consultation with experts and stakeholders. IQWiG’s recommendations are then 
considered by the Joint Committee in issuing coverage and payment directives. Under 
German law, insurance funds must cover any service that is medically necessary, which 
means that cost-effectiveness analysis can only be used to exclude a treatment from cover-
age if at least one equivalent alternative exists.
                    
OVERVIEW
Most Germans receive health coverage through the Statutory Health Insurance 
(SHI) system of sickness funds. Decisions about reimbursement of pharmaceuti-
cals and other medical services (therapeutic and diagnostic procedures) by the 
sickness funds are made by a Federal Joint Committee composed of provider, 
insurer, and patient representatives. The Institute for Quality and Efficiency in 
Health Care (IQWiG) was established in 2004 to provide the committee with 
evidence-based evaluations of the benefits and cost benefits of services, and 
functions in an advisory role. In other words, the analyses and the coverage deci-
sions are split between IQWiG and the Federal Joint Committee, respectively. 
IQWiG and the Federal Joint Committee are funded through a system using rev-
enues from surcharges on SHI payments to providers. In addition to reports on 
coverage recommendations, IQWiG produces health information for consumers 
and patients and working papers on methodological and other issues.
Requests for evaluation of specific health services may come from a vari-
ety of government sources and interested organizations. The Joint Committee 
identifies priority topics for IQWiG, which in turn conducts or commissions an 
evaluation on those topics. IQWiG reviews available evidence and 
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produces recommendations after an extensive process 
of consultation with experts and stakeholders. The 
review process is transparent and public, and does not 
consider confidential commercial information that can-
not be published. IQWiG’s recommendations are then 
considered by the Joint Committee in issuing coverage 
and payment directives.
IQWiG studies focus on the evaluation of bene-
fits and costs of a new service, defined in terms of 
improvement in patient-related outcomes. The cost-
effectiveness component was further cemented on June 
1, 2007, with the implementation of health care reform 
to develop methods for the cost-benefit evaluation of 
drugs to define a ceiling price. Under German law, the 
SHI funds must cover any service that is medically 
necessary. This means that cost-effectiveness analysis 
can only be used to exclude a treatment from coverage 
if at least one equivalent alternative exists. The Joint 
Committee may authorize conditional coverage while 
further data on a treatment are being collected. 
Sometimes its directives leave some options to sick-
ness funds (e.g., to exclude a treatment or negotiate a 
discounted price).
A number of issues have emerged in the early 
years of IQWiG’s operations. First, new drugs and 
inpatient medical services are covered by default and 
are assessed only if the Joint Committee requests an 
evaluation. Germany pays higher prices and covers 
more new drugs than other European countries; more 
rapid evaluations could alleviate this. Second, contro-
versy has surrounded some recommendations because 
of limited time to raise public awareness of the value 
of evidence-based decision-making.
EVIDENCE-BASED POLICY-MAKING IN THE 
GERMAN HEALTH CARE SYSTEM: HISTORY 
AND CURRENT STATUS
About 90 percent of the German people are covered by 
the statutory health insurance (SHI) system, which 
requires enrollment in privately operated sickness 
funds with legal responsibility and joint employer/indi-
vidual financing. Most of the rest have private health 
insurance.1 The growth in new drugs and technologies, 
along with the decrease in the income of the health 
insurance funds, have led to debates over whether ser-
vices such as lifestyle drugs or certain medical ser-
vices like some dental procedures should be covered 
by the sickness funds. Measures in 1992 and after-
wards provided for increased transparency and cost 
control in drug reimbursement and the use of health 
technology assessment to evaluate outpatient medical 
services. The health care reforms of 2003 established 
an evidence-based policy-making process to improve 
quality, provide transparency in coverage decisions, 
and promote patient participation.2,3
Decisions about coverage of pharmaceuticals 
and other medical services under the SHI are made by 
the Federal Joint Committee, which includes members 
from associations of physicians, hospitals, and sick-
ness funds, along with patient representatives. (Patient 
representatives have no vote in the main committee, 
but participate actively in the main committee and sub-
committees.) The committee is responsible for making 
evidence-based decisions about the exclusion of phar-
maceuticals and lifestyle drugs from the SHI fund, 
inclusion and exclusion of other medical care services 
in outpatient care, and exclusion of medical services in 
hospital care. It also makes decisions about disease 
management programs for chronic illnesses, sets refer-
ence prices for medications, and conducts cost-effec-
tiveness analyses and quality assurance of inpatient 
and outpatient care. The committee’s directives are 
binding on sickness funds and providers.4,5,6
For an independent evaluation of intrinsic and 
incremental benefits of pharmaceuticals and other 
medical services, the 2003 legislation required the 
Federal Joint Committee to establish a nonprofit, non-
governmental, independent private law foundation that 
has the legal capacity and is responsible to create and 
maintain the Institute for Quality and Efficiency in 
Health Care (Institut für Qualität und 
Wirtschaftlichkeit im Gesundheitswesen, IQWiG). 
IQWiG was established on June 1, 2004, and is 
responsible for undertaking the evaluation of benefits 
and cost benefits of medical services, based on inter-
national standards of evidence-based medicine in a 
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Unterausschuss). This subcommittee defines and com-
poses maximum reimbursement amount clusters 
(“Festbetrag clusters”) for certain drugs (e.g., drugs 
with similar clinical efficacy and chemical composi-
tion), which it submits to the Joint Committee. In 
cases where the medications cost more than the maxi-
mum reimbursement rate in the market, the Join 
Committee can decide that the patients need to pay for 
the extra costs of these drugs.12,13
Reimbursement of Nonpharmaceutical 
Medical Services
As in the case of pharmaceuticals, the Joint Committee 
makes only negative determinations regarding cover-
age of medical services in hospitals; sickness funds 
cover any service not specifically excluded. For non-
hospital services, however, the committee makes posi-
tive decisions: a new procedure or technology may be 
covered only if the committee has specifically decided 
to include it as a listed service. In making its evalua-
tions, the committee considers not only the benefit of a 
service but also the feasibility of implementing cover-
age, considering, for example, necessary equipment 
and physician training and skills.
The current process of evidence-based policy-
making in Germany is focused on reimbursement deci-
sions. IQWiG is not commissioned to develop guide-
lines for medical practice, though the Federal Joint 
Committee can publish treatment recommendations for 
clinicians based on IQWiG reports. Physicians may 
still prescribe an excluded drug or treatment, but 
patients must usually pay the full cost, with some 
exceptions. A physician may provide an explanation of 
why a patient requires a specific excluded drug and 
request its reimbursement. Additionally, a constitu-
tional court decision in 2005 has specified that, when a 
patient has a life-threatening disease for which no 
alternate treatment is available, the SHI fund must 
cover a treatment for which the chance of success is 
not entirely remote.
When evidence of the benefit of a health service 
is incomplete, the Joint Committee might decide to 
propose a conditional coverage scheme. The treatment 
transparent, scientific, inclusive, independent, and con-
sistent way. In 2007, it was given the additional 
responsibility to develop methods for cost-benefit 
evaluation of drugs in order to define a ceiling price 
and further support competition between SHI provid-
ers (Gesundheitreform 2007 “Gesetz zur Stärkung des 
Wettbewerbs in der gesetzlichen 
Krankenversicherung”).7,8
THE CURRENT PROCESS OF EVIDENCE-
BASED POLICY-MAKING IN GERMANY
The Federal Joint Committee appraises and uses com-
parative effectiveness to develop directives that are 
legally binding for the insurers, providers, and payers 
of health care.9
Reimbursement of Pharmaceuticals
When drugs are approved for marketing, they are usu-
ally immediately reimbursable by the sickness funds, 
with minor exceptions such as cold remedies, over-the-
counter drugs (except for specific age groups), and 
life-style drugs such as those for erectile dysfunction 
or obesity. While the Ministry of Health can exclude 
coverage of some drugs, such as those with unneces-
sary active ingredients,10 on its own, the main process 
for exclusion of pharmaceuticals is through the Federal 
Joint Committee. (There is only a negative list of non-
covered drugs; proposals for a positive coverage list 
have never been implemented.)
A request for evaluation of a drug may be made 
by any of the associations represented on the Joint 
Committee, by patient advocacy and self-help groups, 
or by the Ministry of Health or the Federal commis-
sioner for patient affairs. The committee in turn may 
commission an evaluation by IQWiG, especially when 
coverage is controversial or preliminary review sug-
gests that the evidence is inconclusive.11 IQWiG sub-
mits evaluation results and a recommendation to the 
Joint Committee, which the committee uses to develop 
a directive that, once approved by the Ministry of 
Health, is binding on SHI funds.
The Joint Committee has several subcommit-
tees, including one on pharmaceuticals (Arzneimittel 
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would be reimbursed for a set period, during which 
physicians are responsible to collect specific data 
needed for evaluation.14
THE STRUCTURE, SIZE, FUNDING, AND 
OUTPUTS OF IQWIG
The Federal Joint Committee established the 
Foundation of the Institute for Quality and Efficiency 
in Health Care to establish and define the structure of 
IQWiG. The Foundation has two parts: the Foundation 
Council (Stiftungsrat), and a five-member Foundation 
Board of Directors (Vorstand). The Foundation Board 
of Directors has two members from the health insur-
ance funds, two members from the health providers, 
and one representative from the Ministry of Health. 
Half of the members of the Foundation Council are 
from the National Confederations of Regional 
Associations of the Statutory Health Insurance funds 
and half are from provider organizations. The manage-
ment of IQWiG is independent from the Foundation, 
and receives advice from two committees: the Board 
of Trustees (Kuratorium) and a Scientific Advisory 
Board. The Board of Trustees has 30 members and 
includes representatives from scientific societies, employ-
ers, pharmaceutical companies, and other groups.15
The current structure of IQWiG includes eight 
departments, along with an Institute Management 
Department. The departments are: 1) Pharmaceutical, 
2) Medical Biometry, 3) Health Economics, 4) Health 
Information, 5) Quality of Healthcare, 6) Nondrug 
Interventions, 7) Communication, and 8) Administration. 
IQWiG staff has grown from 11 employees in 2004 to 
more than 90 employees at present. However, the work 
of the Institute is done in collaboration with a wider 
network of German and international experts who pro-
vide consultation and peer review and carry out analy-
ses. The health information department receives feed-
back from focus groups of consumers at the Patient 
University of Hannover (an innovative program that 
provides self-help education for the chronically ill).
IQWiG is funded through surcharges on ser-
vices reimbursed by SHI; the details are determined by 
the Federal Joint Committee. The budget has grown 
from €8 million in 2005 to a planned €15 million in 
2009. This includes salaries, administrative costs, and 
costs for outside experts and consultants.
The products developed by IQWiG in response 
to Joint Committee commissions include full or rapid 
reports, assessing the benefit or cost benefit of medical 
interventions and health information for consumers 
and patients. IQWiG also produces working papers on 
its own initiative, on topics such as reviews of clinical 
Table 1. IQWiG Reports and Other Products
Topics Example
Screening Screening for visual impairment in children younger than 6 years 
Nonpharmacological procedure Negative Pressure Wound Therapy
Health care management  
(Disease Management Program, DMP)
Systematic guideline search and evaluation, as well as extraction and comparison of relevant infor-
mation on obesity, for the preparation of the DMP obesity module
Pharmaceuticals Fixed combinations of corticosteroids and long-acting beta-2-receptor agonists for inhaled use in patients with asthma
Diagnostics Positron emission tomography (PET) and PET/CT in malignant lymphoma
Quality of care Relationship between provider volume and outcomes in the care of preterm infants and neonates with very low birth weight
Patient information Production of an information leaflet for pregnant women to support medical counseling on HIV tests within the framework of the maternity guidelines of the Federal Joint Committee
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guidelines, methodological studies, or evaluations of 
the quality of health services. The following table 
gives some examples of completed outputs.
PRINCIPLES AND VALUES, AIMS  
AND OBJECTIVES
IQWiG is charged by law with the following tasks:
Research on, assessment, and presentation of 1. 
current scientific evidence on diagnostic and 
therapeutic procedures for specific diseases;
Preparation of scientific reports and expert 2. 
opinions on quality and efficiency issues for the 
SHI system, taking into account age, gender, 
and personal circumstances;
Appraisal of evidence-based clinical practice 3. 
guidelines on the epidemiologically most 
important diseases;
Issuance of recommendations on disease man-4. 
agement programs; and 16,17
Provision of understandable evidence-based 5. 
information for patients and public.
IQWiG operates under some general principles:
Inclusiveness: •	 The law requires that providers, 
experts, industry, and patient organizations have 
an opportunity to comment on IQWiG methods 
and recommendations. The draft report plans 
and reports are published online in the public 
domain and stakeholders and the general public 
are encouraged to submit their views and com-
ments. IQWiG provides an email alert service 
notifying subscribers of the publication of draft 
reports and the opportunity to provide com-
ments. Comments can be submitted through writ-
ten correspondence or the submission of written 
documents and evidence.
Transparency: •	 All of the methods and processes 
used in developing IQWiG reports are made 
public, along with the evidence underpinning 
the guidance provided by the report. Unlike 
similar organizations elsewhere, IQWiG does 
not accept confidential commercial information 
furnished by pharmaceutical companies and 
subject to publication restrictions. Instead, a 
standard contract negotiated with the pharma-
ceutical manufacturers’ association specifies the 
types of information that companies should pro-
vide and permits IQWiG to publish any relevant 
data, so that third parties can understand and 
evaluate its processes and methods.
Independence: •	 The system of funding through 
levies on provider charges assures that IQWiG 
is independent of stakeholders or the appropria-
tions process, and any individual involved in 
the reports has to declare their conflicts of inter-
est. The commissioning bodies, the Joint 
Committee or Ministry of Health, clarify the 
scope of commissioned projects as stakeholders 
but do not have any direct involvement in the 
process of delivering the projects.
Scientific rigor and consistency: •	 IQWiG meth-
ods for evaluating the benefits of health services 
are based on internationally recognized stan-
dards of evidence-based medicine. The methods 
for benefit evaluation are set out in a methods 
paper, which is regularly revised by the meth-
ods group of IQWiG. Methods for cost-benefit 
evaluation are under development.18,19
USING COMPARATIVE EFFECTIVENESS 
RESEARCH (CER) TO INFORM POLICY 
DECISIONS
The Federal Joint Committee, the main decision-mak-
ing body of the self-administrated health care system, 
appraises and uses comparative effectiveness research 
(CER) prepared by IQWiG or other sources using a 
detailed evidence-based procedure (paragraph §92 of 
the Social code book V). The committee considers 
needs and costs to develop legally binding directives 
for the insurers, providers and payers of health care.20 
IQWiG is a producer of CER and undertakes synthesis 
of the available evidence to evaluate the benefits and 
cost benefit of drugs and healthcare services for 
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in- and outpatient care. The recommendations of 
IQWiG are only advisory and the Federal Joint 
Committee might decide to follow or not follow the 
recommendations. In the absence of evidence for the 
benefit of health care services, the Federal joint com-
mittee might decide to propose a conditional coverage 
scheme (“Modellvorhaben”). In the latter case, treat-
ment would be reimbursed for a set period of time by 
the health insurance fund, while the physicians would 
be responsible for collecting the needed data to more 
fully evaluate the procedure.21 The research institutes 
could also undertake clinical trials on these medical 
interventions and submit a request to the Federal Joint 
Committee that the medical intervention be reimbursed.
PROCESSES AND METHODS
Process of Preparing Reports in IQWiG
Topic Selection: As noted above, requests for evalua-
tion of specific health services may come from a vari-
ety of government sources and interested organiza-
tions. These applications are considered and prioritized 
by the Joint Committee, taking into account the clini-
cal relevance of the health service and the risk and 
costs associated with it. IQWiG is then commissioned 
to evaluate priority services. In addition, the commit-
tee has given IQWiG a general commission to regu-
larly evaluate the current medical literature, monitor 
developments in medicine and their influence on the 
quality and efficiency of medical services, and under-
take projects based on its own initiative that could pro-
vide useful information or recommendations for the 
improvement of medical services. In 2006, this general 
authorization was amended to specify that IQWiG 
could independently select topics for preparing under-
standable evidence-based health information for 
patients and public through a scientific process.
After IQWiG is commissioned to do an evalua-
tion, an internal project group defines the scientific 
question in consultation with the commissioning 
agency and other relevant groups. A research protocol 
and report plan is prepared and finalized after an 
opportunity for public comment, after which a report 
and recommendations are developed based on 
a literature search and evaluation and synthesis of 
available studies and finalized after public and stake-
holder consultation. External experts are usually 
involved in the process, which includes several further 
stages of internal review.
IQWiG also produces “rapid reports,” which do 
not inform directives by the Joint Committee, but are 
intended to provide up-to-date information on relevant 
health care developments, especially new medical 
technologies. They are subject to peer review but not 
extensive public consultation.
Comments and Hearing: IQWiG allows public 
and stakeholder comment on the report plans and pre-
liminary reports done by the Institute. Each stake-
holder and relevant governmental body is given the 
opportunity to comment or challenge the reports of 
IQWiG with written documents and evidence. Legal 
appeal cannot be made on IQWiG reports as the 
reports and their recommendation are not legally bind-
ing; however, if the directives based on the reports are 
developed, approved and implemented by the Federal 
Joint Committee, challenging the directives necessi-
tates legal appeal.
Methods for Evaluating Patient-Relevant 
Benefit and Cost-Benefit Relationships  
in IQWiG
SHI funds must reimburse any service that is neces-
sary to diagnose or cure a disease, prevent worsening 
of the disease, or alleviate symptoms. Benefit assess-
ments by IQWiG help to determine whether a service 
meets this definition of necessity, taking into consider-
ation both positive and negative effects in comparison 
with other treatments, placebo, or no active treatment. 
IQWiG also assesses the cost-effectiveness of some 
treatments. Under the law, an effective treatment may 
not be excluded from coverage on the basis of its 
costs. However, cost-effectiveness analysis may be 
used to set a maximum reimbursement amount for the 
treatment.
IQWiG undertakes the assessment of the benefit 
and harm of medical services in terms of patient-rele-
vant medical outcomes—that is, outcomes that reflect 
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how the patient feels, functions, or survives. Outcome 
measures considered in this context include mortality, 
morbidity (complaints and complications), health-
related quality of life, effects on duration of the illness, 
adverse effects of the intervention, and patient satisfac-
tion. Topic-specific outcomes to be measured are iden-
tified in consultation with affected individuals or 
patient organizations.
The latest working paper on cost-benefit evalu-
ation methodology recommends that an “efficiency 
frontier” should be constructed for each therapeutic 
area to make it possible to compare the relative costs 
and benefits of alternative therapies. The plot has two 
axes, a horizontal one reflecting the total net costs per 
patient from the perspective of the insurers of the SHI 
funds, and a vertical one, which reflects health benefits 
assessed by IQWiG that can be parameterized with 
actual clinical measures. The benefit should always be 
established before the economic evaluation and should 
be derived from a rigorous assessment of patient-rele-
vant outcomes. Hence, prior to any cost-effectiveness 
evaluation, a benefits evaluation is needed. For the 
economic evaluation, IQWiG submits a budget impact 
analysis to the Joint Committee, which takes it into 
consideration along with other factors such as afford-
ability. This method cannot be used for new drugs with 
no available alternative therapy, meaning sickness 
funds must continue to reimburse these as they do 
currently.22
PATIENT INFORMATION
IQWiG’s patient health information Web site (http://
www.informedhealthonline.org) was launched in 
February 2006. It provides understandable health 
information for patients and the public to support 
informed decision-making about health issues and to 
improve public understanding of scientific concepts 
and evidence-based medicine. The content is based on 
scientific evidence, especially systematic reviews, and 
uses evidence-based techniques to communicate the 
information in nondirective and neutral language. 
Topics are identified through an internal horizon scan-
ning process and are approved by the internal steering 
committee. Health information is developed through a 
Figure 1. Proposed Process for Economic Evaluations
IQWiG, Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System. Version 1.1, Oct. 9, 2008. 
Available at: http://www.iqwig.de/download/08-10-14_Methods_of_the_Relation_of_Benefits_to_Costs_v_1_1.pdf.
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rigorous scientific process, which includes identifying 
and assessing the evidence, peer review, and a stake-
holder consultation process.23,24 The products can be in 
the form of feature articles, fact sheets and research 
summaries, patient narratives, interactive features, and 
animated films.25
THE MEDIA AND PUBLIC PERCEPTIONS
Since the publication of the first draft reports, IQWiG 
has received intense media attention, critiquing or 
appraising the reports and patient information pub-
lished by the Institute. The involvement of stakehold-
ers and the general public in the process of preparing 
reports improves the transparency and inclusiveness of 
the reports but also causes debate, criticisms, and dis-
cussion. For example, pharmaceutical companies or 
associations have issued press releases during the pro-
cess of preparing and publishing reports.
There are several reasons for the intense media 
coverage that IQWiG has received. German pharma-
ceutical policies allow reimbursement of most new 
drugs immediately after their marketing approval by 
licensing authorities. If the Federal Joint Committee 
then decides to commission IQWiG to evaluate a prod-
uct, this represents a threat to the manufacturer, 
because a negative report could mean that its pharma-
ceutical or medical service might be excluded from 
SHI reimbursement. In addition to this, the Federal 
Joint Committee usually selects and prioritizes topics 
for evaluation that have a potential impact on health 
services in Germany, possibly resulting in new direc-
tives for the SHI funds, and for which primary litera-
ture search and evaluation indicates that the evidence 
base may be inconclusive or controversial.26,27
IMPACT ON POLICY AND PRACTICE: 
SELECTED CASE STUDIES AND  
OVERALL TRENDS
The interrelated health care system in Germany facili-
tates the implementation of the recommendations of 
IQWiG reports in the system. Full reports from IQWiG 
are submitted to the Federal Joint Committee and the 
committee takes them into consideration as a basis for 
developing directives for the health care system. These 
directives are mandatory for the SHI funds, but there 
can sometimes be opportunities, within the framework 
of a directive, for different sickness funds to adopt dif-
ferent coverage or payment options.28,29
For example, one of the first full reports pro-
duced by IQWiG was on rapid-acting insulin ana-
logues for the treatment of diabetes mellitus type 2. 
The report found no additional benefit of insulin ana-
logues compared with human insulin. On the basis of 
this finding, the Federal Joint Committee decided that 
these analogues would not be reimbursed by the SHI 
funds as a long as they were more expensive than 
human insulin. Some SHI funds responded by exclud-
ing insulin analogues from coverage, while others 
negotiated discounts from the manufacturers.30
LESSONS LEARNED: A CRITICAL VIEW
Earlier Benefit Assessment of Drugs and 
Medical Services
The SHI funds allow immediate reimbursement of any 
pharmaceutical that has received marketing approval, 
at any price the producer sets. Similarly, the policy of 
having only a negative list of excluded procedures for 
inpatients means that nonpharmacy services provided 
in hospitals are covered by default. Assessment of the 
benefits of these medical services and pharmaceuticals 
is undertaken only when the Joint Committee decides 
to request an evaluation by IQWiG. Under current 
rules, Germany pays the highest prices for drugs in 
Europe and has more new drugs available than other 
European countries. An earlier benefit evaluation of 
drugs and medical services could prevent additional 
costs and the harm of medical services without a proof 
of benefit.
Limited Time to Raise Public Awareness
The previous unlimited access to pharmaceuticals has 
made it difficult for the patient and public to accept 
the exclusion of some of the drugs from SHI cover-
age.31 In addition, IQWiG was given a number of com-
missions immediately after its establishment, and was 
not provided with the time to raise awareness on the 
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need for a more evidence-based approach for deciding 
the inclusion or exclusion of medical services. This 
resulted into disputes and criticisms of the first IQWiG 
reports and discussions regarding the process of stake-
holder consultation. The longer time period currently 
devoted to the development of cost-evaluation meth-
ods has provided more opportunities to discuss the 
way methods are developed, and may help different 
stakeholders get acquainted with the need for a more 
systematic approach for cost-benefit evaluation.
Need for More Targeted Primary Research
In the first proposals to establish IQWiG in 2004, it 
was suggested that IQWiG should have its own trial 
coordination department, to help address the lack of 
primary studies for important clinical questions. The 
plan was that this IQWiG department would make rec-
ommendations on how necessary clinical trials should 
be designed and conducted. It would also coordinate 
and provide ongoing advice on the research work con-
ducted in scientific institutions in Germany and 
abroad. This proposal was not implemented because of 
several issues:
The current budget of many clinical trials 1. 
comes from the industry and there were con-
cerns about the potential effects of collaboration 
between industry and an independent Institute 
in undertaking industry-funded trials. On the 
other hand, if industry was not to be considered 
as a main source for funding for clinical trials, 
there was a question of who should be funding 
necessary trials.
If the Institute was to be involved in coordinat-2. 
ing primary trials, there was a possibility that 
the involvement would bias its assessment of 
those trials in the evidence-synthesis stage. 
Despite the need for collaboration between the 
evidence synthesis and primary research sec-
tors, appropriate strategies would have had to 
be put in place to ensure the independence of 
the two sectors.
Need for Regulation to Access 
Unpublished Data
IQWiG’s access to unpublished data for benefit assess-
ment of drugs and medical interventions is dependent 
on the willingness of pharmaceutical companies to 
provide these data; there is no regulation requiring that 
the companies do so. This can lead to publication bias 
in the benefit assessment of medical services, espe-
cially in cases when the published data are scarce. A 
regulation for obligatory availability of data for the 
benefit assessment of drugs and medical services 
might help in ensuring a more thorough assessment of 
the benefit and harm of medical services.
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